The National Consumers League Applauds the Trump Administration For Lowering the Price of GLP-1 Weight Loss Drugs
Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829
Washington, DC – On behalf of the estimated 100,000 million US adults with obesity, many of whom are seeking treatment with FDA-approved anti-obesity medicines, the National Consumers League (NCL) applauds the Trump Administration for negotiating lower prices for the popular GLP-1 (glucagon-like peptide-1) weight loss drugs, Wegovy© (semaglutide) and Zepbound© (tirzepatide), so these medicines are more accessible to those needing quality obesity care.
According to an agreement the White House reached with the manufacturers of Wegovy and Zepbound, as of mid-2026, the Medicare program will purchase injectable semaglutide and tirzepatide – and later the pill forms when approved by the FDA — at $149 per month for the lowest dose and $245 per month for larger doses. This means that Medicare will be able to cover GLP-1 weight loss drugs for the first time, with Medicare beneficiaries responsible for co-pay of just $50 per month. Moreover, state Medicaid programs will benefit from these discounts, thereby allowing more people with obesity to receive quality obesity care in the country.
Also of note, starting in January 2026, Americans not eligible for Medicare or Medicaid will be able to buy Wegovy and Zepbound directly from the government website, Trumprx.gov, for $350 or less per month. This represents a significant discount from the price the manufacturers currently offer to consumers through their direct-to-consumer online pharmacy programs.
Collectively, the actions by the Administration will improve the lives of millions of Americans with obesity, who for too long, have been denied access to medicines that are clinically effective in achieving significant weight loss.
However, NCL joins with other members of the obesity community in calling on Congress to pass the Treat and Reduce Obesity Act (TROA) this year. By enacting this legislation, Congress will ensure that Medicare beneficiaries have coverage for GLP-1 drugs. At the same time, TROA will expand access to intensive behavioral therapy (IBT) in more clinical settings, allowing more adult Americans to receive counseling that promotes sustained weight loss through high intensity interventions on diet and exercise.
###
About the National Consumers League (NCL)
The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.
